Group 1 - Triangle Defense signed a gas turbine project development and framework order agreement with Siemens Energy [1] - The development agreement allows Triangle Defense to qualify for supplying specific items to Siemens Energy, detailing technical prerequisites and standards [1] - Triangle Defense specializes in the research, production, and sales of forged products in aviation, aerospace, and shipping industries [1] Group 2 - Aerospace Hongtu was suspended from military procurement for three years due to alleged violations during a procurement activity [2] - The suspension will last from July 6, 2024, to July 6, 2027, affecting the company's participation in military material procurement [2] - Aerospace Hongtu focuses on satellite operations and data collection [3] Group 3 - Kaili Medical's executives purchased a total of 460,000 shares, investing approximately 13.15 million yuan [4] - The average purchase prices were 28.70 yuan and 28.53 yuan per share [4] - Kaili Medical is engaged in the research, production, and sales of medical diagnostic and treatment equipment [5] Group 4 - Muyuan Foods reported a 22.28% year-on-year decline in sales revenue from live pigs in October, totaling 10.33 billion yuan [6] - The average selling price of live pigs decreased by 32.73% year-on-year to 11.55 yuan per kilogram [6] - Muyuan Foods is involved in pig farming and slaughtering [7] Group 5 - Niuwei Co. plans to acquire 40% of its subsidiary Dongwu Machinery for 139 million yuan, aiming for full ownership [8] - Niuwei Co. specializes in the research, manufacturing, and sales of industrial valves [9] Group 6 - Jinlong Automobile reported a 14.71% year-on-year decline in bus sales in October, with 4,121 units sold [10] - Jinlong Automobile focuses on the production and sales of bus products [10] Group 7 - ST Tianshan reported a 242.54% year-on-year increase in sales revenue from live livestock in October, totaling 13.35 million yuan [11] - The company sold 1,367 head of livestock, marking a significant increase compared to previous periods [11] - ST Tianshan is involved in the breeding and sales of cattle and dairy products [12] Group 8 - Ningbo Port expects a 12.4% year-on-year increase in container throughput in October, reaching 4.56 million TEUs [13] - The total cargo throughput is projected to be 99.6 million tons, a 5.3% increase year-on-year [13] - Ningbo Port engages in port handling and logistics services [13] Group 9 - Amcare Pharma received approval for supplementary drug applications and clinical trials for its products [14] - The company is focused on new drug development and utilizes a MAH model for production [14] Group 10 - Lude Environment plans to change its stock name to "Lude Technology" while keeping its full name and stock code unchanged [15] - The company specializes in waste treatment and resource utilization technologies [15] Group 11 - Hualan Co. plans to increase its stake in the company by investing between 30 million and 60 million yuan [16] - The maximum purchase price is set at 58.08 yuan per share [16] - Hualan Co. focuses on the development and sales of packaging materials for injectable drugs [16] Group 12 - Caina Co. is using 140 million yuan of idle funds to purchase structured deposits from a bank, with expected annual yields between 0.70% and 1.85% [17] - Caina Co. specializes in the research, production, and sales of injection and laboratory consumables [17] Group 13 - Zhenghong Technology reported a 52.80% year-on-year decrease in sales revenue from live pigs in October, totaling 4.32 million yuan [18] - The company sold 400 head of pigs, marking a significant decline compared to previous periods [18] - Zhenghong Technology is involved in feed production and pig farming [18] Group 14 - Caida Securities received approval from the CSRC to issue bonds totaling up to 6 billion yuan [19] - The company is engaged in securities brokerage, investment banking, and asset management [19] Group 15 - Jiayuan Technology signed a copper foil supply framework agreement with CATL, establishing a long-term partnership [20] - The agreement includes collaboration in the supply and production of materials for new battery technologies [20] Group 16 - Haikong Group announced the resignation of its general manager due to personal career planning [21] - The company is involved in automotive passenger transport and related services [21] Group 17 - Beizhi Technology's application to acquire 100% of Suzhou Suike Intelligent Technology has been accepted by the Shanghai Stock Exchange [22] - The company specializes in intelligent logistics systems and equipment [22] Group 18 - Yikang Pharma's subsidiary received approval for clinical trials of a new injection for chronic hepatitis B [23] - The company focuses on the production and sales of raw and formulated pharmaceutical products [23] Group 19 - Hengyuan Coal Power plans to acquire 100% of two coal companies for 440 million yuan [24] - The acquisition includes assuming debts totaling 1.137 billion yuan [24] - Hengyuan Coal Power is involved in coal mining and sales [24] Group 20 - Yangpu Medical announced the cancellation of a production arrangement for a medical device [25] - The company specializes in precision medical and testing services [25] Group 21 - Kailong High-Tech plans to establish a 195 million yuan industry fund focusing on unlisted companies [26] - The company is involved in air pollution control and new energy management systems [26] Group 22 - Yingli Co. received approval for its application to acquire a majority stake in a company [27] - The company specializes in precision electronic components and related manufacturing [27] Group 23 - Tianyi Medical's arterial-venous puncture device received EU MDR certification, valid until January 2028 [28] - The company focuses on medical devices for blood purification and care [28] Group 24 - Chuangyuan Co. appointed a new president, effective until the end of the current board term [29] - The company specializes in the design and production of paper products [29] Group 25 - Shanghai Laishi's new indication for a drug received clinical trial approval [30] - The company focuses on the production and sales of blood products [30] Group 26 - Fengmao Co. plans to issue convertible bonds to raise up to 520 million yuan for expansion and working capital [31] - The company specializes in precision rubber components [31] Group 27 - Yinuo Si's shareholder plans to transfer 3% of the company's shares through an inquiry process [32] - The company provides comprehensive R&D services in the biopharmaceutical sector [32] Group 28 - Phoenix Shipping plans to use up to 50 million yuan of idle funds for cash management [33] - The company is involved in dry bulk shipping and logistics services [33] Group 29 - Xingyuan Zhuomei received a notification to supply magnesium alloy components worth 2.021 billion yuan to a new energy vehicle manufacturer [34] - The project is expected to start mass production in the third quarter of 2026 [34] Group 30 - Landai Technology's subsidiary plans to sell electric drive assembly assets for 110 million yuan [35] - The company specializes in power transmission and display technology [35] Group 31 - Yuexiu Capital plans to distribute a cash dividend of 0.90 yuan per share [36] - The company is involved in asset management and private equity [36] Group 32 - Northeast Securities plans to distribute a cash dividend of 1.00 yuan per share, totaling 234 million yuan [37] - The company focuses on wealth management and investment banking [37] Group 33 - Jinguang Electric won a bid for a project from the State Grid worth 21.7976 million yuan [38] - The company specializes in the research and manufacturing of power distribution equipment [39] Group 34 - Huarong Co. plans to repurchase shares worth between 40 million and 125 million yuan [40] - The company focuses on the production and sales of explosion-proof electrical equipment [40] Group 35 - Baiyang Pharma signed a distribution agreement for a blood product, gaining exclusive rights in specific markets [41] - The company specializes in the development and commercialization of medical innovations [41] Group 36 - Li Qun Co.'s director plans to reduce his stake by up to 71,000 shares due to personal financial needs [42] - The company is involved in retail and logistics services [42] Group 37 - Su Li Co.'s shareholder plans to reduce his stake by up to 0.48% of the company's shares [43] - The company specializes in the production and sales of fine chemical products [43] Group 38 - Shenzhen Ruijie obtained a commitment letter for a stock repurchase loan of up to 15.3 million yuan [44] - The company provides project management and evaluation services [44] Group 39 - Fudan Zhangjiang's shareholder plans to reduce his stake by up to 1% of the company's shares [45] - The company focuses on biopharmaceutical research and development [45] Group 40 - Ningbo Zhongbai's shareholder plans to reduce his stake by up to 1% of the company's shares [46] - The company is involved in retail and wholesale operations [46] Group 41 - Jingyi Co. announced a change in control due to a judicial auction of shares [47] - The company specializes in copper processing and digital carbon services [47] Group 42 - Luoping Zinc Electric's subsidiary obtained a new safety production license for mining operations [48] - The company focuses on hydropower and mining activities [48]

Core Viewpoint - Yuyuan Pharmaceutical announced that its subsidiaries have received approval from the National Medical Products Administration to conduct Phase I clinical trials for YKYY013 injection, aimed at treating chronic hepatitis B virus infection [1] Group 1: Company Developments - Yuyuan Pharmaceutical's subsidiary, Beijing Yuyuan Kechuang Pharmaceutical Technology Co., Ltd., and Hangzhou Tianlong Pharmaceutical Co., Ltd. have obtained the clinical trial approval [1] - YKYY013 injection is a chemically synthesized double-stranded siRNA drug that utilizes N-acetylgalactosamine ligands [1] Group 2: Product Details - YKYY013 works through RNA interference to effectively silence the messenger RNA of the HBV genome, thereby inhibiting the production of hepatitis B pathogen proteins and suppressing HBV replication [1] - The drug aims to create conditions for host immune reconstitution, ultimately achieving functional cure for hepatitis B [1]

Core Viewpoint - Yuyuan Pharmaceutical (688658.SH) has received approval from the National Medical Products Administration for its subsidiary Yuyuan Kechuang and Hangzhou Tianlong to conduct Phase I clinical trials for YKYY013 injection, aimed at treating chronic hepatitis B virus infection [1] Company Summary - YKYY013 injection is a chemically synthesized double-stranded siRNA drug developed by Yuyuan Kechuang and Hangzhou Tianlong, utilizing an N-acetylgalactosamine (GalNAc) ligand [1] - The drug works through RNA interference to effectively silence the HBV genome's messenger RNA (mRNA), thereby inhibiting the production of hepatitis B pathogen proteins and suppressing HBV replication [1] - The ultimate goal of YKYY013 is to create conditions for host immune reconstitution, leading to the functional cure of hepatitis B [1] Industry Summary - The approval for clinical trials indicates a significant advancement in the treatment options available for chronic hepatitis B virus infections, which remains a major public health concern globally [1]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 证券代码：688658 证券简称：悦康药业 公告编号：2025-046 悦康药业集团股份有限公司 关于自愿披露子公司 YKYY013 注射液获得国家药品 监督管理局临床试验批准的公告 4、申请人：北京悦康科创医药科技股份有限公司、杭州天龙药业有限公司 悦康药业集团股份有限公司（以下简称"公司"）子公司北京悦康科创医药 科技股份有限公司（以下简称"悦康科创"）、杭州天龙药业有限公司（以下简 称"杭州天龙"）于近日获得国家药品监督管理局（以下简称"NMPA"）核准 签发的关于 YKYY013 注射液用于治疗慢性乙型肝炎病毒感染的《药物临床试 验批准通知书》，公司将开展本品 I 期临床试验。现将相关情况公告如下： 5、申报阶段：临床试验 一、临床批件主要内容： 3、通知书编号：2025LP02896 4、申请适应症：慢性乙型肝炎病毒感染 1、药品名称：YKYY013 注射液 2、受理号：CXHL2500882 6、审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查， 20 ...

悦康药业集团股份有限公司 2025 年第二次临时股东大会会议资料 悦康药业集团股份有限公司 2025 年第二次临时股东大会 会议资料 2025 年 11 月 悦康药业集团股份有限公司 2025 年第二次临时股东大会会议资料 目 录 | 2025 | 年第二次临时股东大会会议须知 | 2 | | --- | --- | --- | | 2025 | 年第二次临时股东大会会议议程 | 4 | | 2025 | 年第二次临时股东大会会议议案 | 6 | 1 悦康药业集团股份有限公司 2025 年第二次临时股东大会会议资料 悦康药业集团股份有限公司 2025 年第二次临时股东大会会议须知 为了维护全体股东的合法权益，确保股东大会的正常秩序和议事效率，保证 大会的顺利进行，根据《中华人民共和国公司法》（以下简称"《公司法》"）、 《中华人民共和国证券法》（以下简称"《证券法》"）、《上市公司股东会规则》 以及《悦康药业集团股份有限公司章程》（以下简称"《公司章程》"）的相关规 定，认真做好召开股东大会的各项工作，特制定本须知： 一、为保证股东大会的严肃性和正常秩序，切实维护股东的合法权益，除出 席会议的股东及股东代表、 ...

Core Viewpoint - Yuyuan Pharmaceutical (688658) announced that its subsidiary Yuyuan Kechuang and Hangzhou Tianlong have recently received approval from the National Medical Products Administration for the clinical trial of YKYY013 injection for the treatment of chronic hepatitis B virus infection [1] Group 1 - The company will initiate Phase I clinical trials for YKYY013 injection [1]

Core Viewpoint - YKYY013 injection, developed by the company and Hangzhou Tianlong Pharmaceutical, has received approval from the NMPA for clinical trials aimed at treating chronic hepatitis B virus infection [1] Group 1: Company Developments - The company's subsidiary, Beijing YK Pharmaceutical Technology Co., Ltd. (referred to as "YK Technology"), has been granted a clinical trial approval notice for YKYY013 injection [1] - The clinical trials will focus on the first phase of testing for YKYY013 injection [1] Group 2: Product Details - YKYY013 injection is a chemically synthesized double-stranded siRNA drug that utilizes an N-acetylgalactosamine (GalNAc) ligand [1] - The drug works through RNA interference to effectively silence the HBV genome's messenger RNA (mRNA), thereby inhibiting the production of hepatitis B viral proteins and replication [1] - The ultimate goal of YKYY013 is to achieve functional cure for hepatitis B by creating conditions for host immune reconstitution [1]

Core Viewpoint - YKYY013 injection, developed by Yuyuan Pharmaceutical's subsidiary and Hangzhou Tianlong Pharmaceutical, has received approval from NMPA for clinical trials targeting chronic hepatitis B virus infection [1] Company Summary - Yuyuan Pharmaceutical's subsidiary, Beijing Yuyuan Kechuang Pharmaceutical Technology Co., Ltd., and Hangzhou Tianlong Pharmaceutical have jointly developed YKYY013 injection [1] - The drug is a chemically synthesized double-stranded siRNA that utilizes N-acetylgalactosamine (GalNAc) as a ligand [1] - The mechanism of action involves RNA interference to silence the HBV genome's messenger RNA, thereby inhibiting the production of hepatitis B viral proteins and replication [1] Industry Summary - The approval for YKYY013 marks a significant advancement in the treatment options for chronic hepatitis B virus infection [1] - The drug aims to create conditions for immune reconstitution in patients, potentially leading to functional cure for hepatitis B [1]

Core Viewpoint - Yuyuan Pharmaceutical's subsidiary Yuyuan Kechuang and Hangzhou Tianlong have received approval from the National Medical Products Administration for the clinical trial of YKYY013 injection for the treatment of chronic hepatitis B virus infection, marking a significant step in the drug's development [1] Group 1 - The YKYY013 injection is a self-developed chemical-synthesized double-stranded siRNA drug [1] - Preclinical studies have shown significant HBV virus suppression activity and good safety profile for YKYY013 [1] - The drug has also received clinical trial approval from the U.S. FDA recently [1] Group 2 - The initiation of Phase I clinical trials is set to begin following the approval [1] - The company acknowledges that drug development involves long cycles, multiple stages, and high risks, which contribute to uncertainties [1] - There is no significant impact on the company's recent performance due to the drug's development status [1]

Group 1 - The core viewpoint of the news is that Yuyuan Pharmaceutical has seen a 5% increase in stock price, reaching 21.62 CNY per share, with a total market capitalization of 9.729 billion CNY [1] - Yuyuan Pharmaceutical focuses on the research and production of high-end chemical drugs, with significant revenue contributions from cardiovascular drugs, digestive system drugs, diabetes medications, and anti-infection drugs [1] - The main products contributing to the company's revenue include Ginkgo biloba extract injection, Tianma injection, Lansoprazole injection, Omeprazole enteric-coated capsules, Metformin sustained-release tablets, Cefuroxime sodium injection, and Ceftriaxone sodium injection [1] Group 2 - Huashan Fund has a significant holding in Yuyuan Pharmaceutical, with the Huashan CSI 1000 Index Enhanced A fund holding 10,500 shares, representing 0.4% of the fund's net value [2] - The Huashan CSI 1000 Index Enhanced A fund has achieved a year-to-date return of 25.63% and a one-year return of 28.95% [2] - The fund manager, Zhang Xu, has a tenure of 5 years and 168 days, with the best fund return during this period being 144.8% [3]